ARS Pharmaceuticals (SPRY) Debt Ratio (2020 - 2026)

ARS Pharmaceuticals (SPRY) posted Debt Ratio of 0.34 for Q1 2026, up 14.11% sequentially from 0.29 in Q4 2025.

ARS Pharmaceuticals (SPRY) Debt Ratio (2020 - 2026) Analysis & Trends

ARS Pharmaceuticals has reported Debt Ratio for 4 years, with the latest figure at 0.34 in Q1 2026.

Quarterly Debt Ratio changed N/A year-over-year to 0.34 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.34 (changed N/A YoY) and the FY2025 annual result came in at 0.29, changed N/A from the prior year.
Debt Ratio improved to 0.34 in Q1 2026 per SPRY's latest filing, from 0.29 in the prior quarter.
Over five years, Debt Ratio peaked at 0.34 in Q1 2026 and troughed at 0.26 in Q3 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.05
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.12
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.47
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.26
10	ARS Pharmaceuticals	561.88 Mn	418.03 Mn	-	0.39

Historic Data

Download Data

Date	Value
Jun 30, 2026	0.39
Mar 31, 2026	0.34
Dec 31, 2025	0.29
Sep 30, 2025	0.26
Dec 31, 2021	0.08
Mar 31, 2021	0.00
Dec 31, 2020	0.00